Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "500k fc points price Buyfc26coins.com is FC 26 coins official site..uOKm"

Looking for quality documents?
external link icon
Repligen Reports Third Quarter 2014 Financial Results
Product Revenue Increases 24% to $15.2 Million Product Gross Profit Increases 26% to $8.2 Million Conference Call and Webcast Today at 8:30 a.m. EST WALTHAM, Mass., Nov. 6, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today reported financial results for its third quarter ended September 30, 2014. The Company's financial and business highlights for the third quarter and year-to-date follow, as well as updated financial guidance for the year 2014. Third Quarter Financial Highlights: Product revenue for the third quarter of 2014 was $15.2 million, an increase of 24%, compared to $12.2 million in product revenue for the third quarter of 2013. Total revenue for the third quarter of 2014 was $15.3 million, compared to $18.8 million for the third quarter of 2013. The 2013 quarter included $6.6 million in royalty and other revenue, of which $4.8 million was royalty revenue from Bristol-Myers Squibb based on its U.S. sales of Orencia ® under an agreement that expired on December
external link icon
Repligen to Report Second Quarter 2013 Financial Results
WALTHAM, Mass., July 18, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that it will report second quarter 2013 financial results on Thursday, August 1, 2013. The Company will issue a press release before the market opens, and will host a conference call at 9:00 a.m. EDT to discuss financial results for the reporting period ended June 30, 2013. Repligen's second quarter conference call will be accessible by dialing (877) 280-4960 for domestic callers or (857) 244-7317 for international callers. Dial-in participants must provide the passcode 52303386. Alternatively, an audio webcast will be accessible via the Investor section of Repligen's website www.repligen.com . Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for international callers. Replay listeners must provide the passcode 22671187. About Repligen Corporation
external link icon
Repligen To Report Third Quarter of 2012 Financial Results
- Webcast and Conference Call to Be Held Thursday, November 8, 9:00 a.m. EST - Repligen Corporation (NASDAQ:RGEN) today announced that it will report financial results for the third quarter of 2012 before the NASDAQ Global Market opens on Thursday, November 8. The earnings press release will be followed by a conference call and webcast at 9:00 a.m. EST. The event will be hosted by Walter C. Herlihy, Ph.D., President and CEO of Repligen, who will discuss financial results for the third quarter and year-to-date and provide a corporate update. Repligen’s third quarter conference call will be accessible by dialing (800) 260-8140 for domestic callers or (617) 614-3672 for international callers. Dial-in participants must provide the passcode 85324503 . Alternatively, an audio webcast will be accessible via the Investors section of Repligen’s website www.repligen.com . Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in
external link icon
Repligen Reports Third Quarter 2013 Financial Results
- Product Revenue Grows 10% for the Quarter - - Net Income Grows 226% to $5.9 Million - - Earnings Conference Call and Webcast Today at 9:00 a.m. EST - WALTHAM, Mass., Nov. 7, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today reported financial results for the third quarter ended September 30, 2013. Below are the Company's financial and business highlights for the third quarter, financial guidance for the year and dial-in numbers for today's conference call. Third Quarter 2013 Financial Highlights Bioprocessing product revenue for the third quarter of 2013 was $12.2 million, an increase of approximately10% over the third quarter of 2012.
  Total revenue for the third quarter of 2013 was $18.8 million, an increase of approximately 25% over the third quarter of 2012.
  Bioprocessing product gross profit margin was 53.5% for the third quarter of 2013, compared to 42.3% during the third quarter of 2012.
  Net income increased to $5.9 million
external link icon
Repligen Reports Third Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
Reports quarterly revenue of $69.4 million, representing 40% reported growth and 28% organic growth year-over-year
Raises revenue guidance to $267-$270 million for full year 2019, representing 31%-32% organic growth WALTHAM, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2019. Provided in this press release are financial highlights for the three- and nine-month periods ended September 30, 2019, updated financial guidance for the fiscal year 2019, and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “We are pleased with our strong performance in the third quarter, reporting over $69 million in revenue and robust organic growth of 28%. Our filtration and chromatography franchises continued to track ahead of expectations and in process analytics, our C
news icon
Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic Solutions
corporate icon
Continuous Manufacturing
FROM BATCH TO CONTINUOUS Continuous manufacturing is a method for manufacturing pharmaceutical products from end-to-end on a single, uninterrupted production line. The aim is to eliminate batch inefficiencies that result in process stoppages, long hold times, and sub-optimal facility utilization.
publications icon
Evaluating DNA purity ratio determination with the CTech™ SoloVPE® System White Paper
Spectrophotometric analysis is one of the most common techniques used to quantitate nucleic acids in a solution. However, traditional fixed-pathlength spectrophotometers have limitations when determining the purity ratios of these molecules. In this study, the CTechTM SoloVPE system assessed theoretical DNA purity ratios by utilizing its variable pathlength method, known as Slope Spectroscopy. The method was evaluated by assessing the specificity, intermediate precision, repeatability, linearity, and accuracy of the theoretical purity ratios. The observed purity ratios from the SoloVPE system demonstrated great comparison to the theoretical purity ratios, verifying the SoloVPE system’s slope spectroscopy method to be preferable for this application. Authors: Nigel Herbert, Drusha Purohit, Hannah Mignault
corporate icon
Viral Vectors
Adeno-associated virus (AAV) is the most common viral vector used in gene therapy bioprocessing. Other viral vectors include adenovirus, lentivirus, retrovirus, oncolytic virus, and virus-based vaccines.
corporate icon
Viral Vector Manufacturing
Adeno-associated virus (AAV) is the most common viral vector used in gene therapy bioprocessing. Other viral vectors include adenovirus, retrovirus, exosomes, oncolytic virus, and virus-based vaccines.
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support